

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Sativa Wellness Group Inc. (the "Issuer").

Trading Symbol: SWEL

Number of Outstanding Listed Securities: 351,012,769

Date: April 30, 2021

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Company announced that it has closed the first tranche of its non-brokered private placement of units of the Company (each, a "Unit") previously announced on February 24, 2021 (the "Offering"). In this closing, the Company issued an aggregate of 45,888,730 Units at a price of C\$0.07875 per Unit for aggregate gross

proceeds of C\$3,613,737.49. Each Unit is comprised of one common share (each, a "Share") and one-half of one common share purchase warrant (each whole warrant, a "Warrant"). Each Warrant will entitle the holder to purchase one common share in the capital of the Company (a "Warrant Share") at a price of C\$0.105 per Warrant Share until March 31, 2023.

In conjunction with the first tranche of the Offering, the Company issued and paid 2,531,098 finder's units (each, a "Finder's Unit") and 2,531,098 finder's warrants (each, a "Finder's Warrant") to Canaccord Genuity Corp. Each Finder's Unit consists of one common share (each, a "Finder's Share") and one-half of one Finder's Warrant. Each Finder's Warrant entitles the holder thereof to purchase one common share of the Company at an exercise price of C\$0.105 per common share up to and including March 31, 2023.

As part of the first tranche of its non-brokered private placement of units of the Company Clive Standish, one of the board of directors took part.

Before this placement Clive Standish held 83,768 shares and 83,768 warrants in Sativa Wellness. As part of this placement Exhall Pty Ltd, a company related to Clive Standish, purchased 13,000,000 Units at a price of C\$0.07875 per Unit for aggregate gross proceeds of C\$1,023,750. The total number of shares Clive has an interest in directly or indirectly is 13,083,768 common shares which represents 3.73% of the company's shares and the total number of warrants he has an interest in is 6,586,768.

All securities issued under the first tranche of the Offering will be subject to a statutory hold period expiring on August 1, 2021, in accordance with applicable Canadian securities laws.

The proceeds from the Offering will be used for working capital and investment across the whole wellness business.

The Company announced that the Company's subsidiary, PhytoVista Laboratories, has been granted accreditation to ISO/IEC 17025:2017 - General requirements for the competence of testing and calibration laboratories.

Accreditation for the testing of cannabinoids, has been granted by United Kingdom Accreditation Service (UKAS), the UK governments appointed National Accreditation Body. The accreditation process determines the technical competence and integrity of organisations such as those offering testing services. ISO17025 accreditation offers the Company a competitive advantage in regulated markets where organisations are required to test with an accredited laboratory. This development also positions the Company well to take advantage of a growing international market and developing regulatory landscape. The Company plans to increase the scope of testing covered by accreditation and penetrate other areas of testing, whilst continuing to develop and expand cannabinoid testing capabilities.

FORM 7 – MONTHLY PROGRESS REPORT

October 2020

Page 2

2. Provide a general overview and discussion of the activities of management.

None to report

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

The Company announced that it is now listed on the United Kingdom government website to offer 2 and 8 day quarantine tests (for travellers returning to the UK.

The Return Tests are a significant addition to the Company's current offering of COVID-19 tests for travellers leaving the UK and will impact positively on the Company's revenues, that continue to build. There are now 24 Goodbody clinics offering COVID-19 testing and the Company is confident that its previously announced target of 30 testing clinics will be met on or before the end of April.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None to report

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

None to report

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None to report

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None to Report.

FORM 7 – MONTHLY PROGRESS REPORT

8. Describe the acquisition of new customers or loss of customers.

None to Report.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

None to Report.

10. Report on any employee hiring's, terminations or lay-offs with details of anticipated length of lay-offs.

None to Report.

11. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None to report

12. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None to report

13. Provide details of any securities issued and options or warrants granted.

None to report

14. Provide details of any loans to or by Related Persons.

None to report

15. Provide details of any changes in directors, officers or committee members.

The Company announced the appointment of Marc Howells as Director and Chief Executive Officer and Anne Tew as Director and Chief Financial Officer of the Company.

Jeremy Thomas resigned as Interim Chief Executive Officer and Joseph Colliver ceased as Chief Financial Officer following his resignation, previously announced on February 4th 2021. Jeremy Thomas will continue in his role as Executive Chairman.

16. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

FORM 7 – MONTHLY PROGRESS REPORT

October 2020

Page 4

None to report


Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were/is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated May 7, 2021.

Anne Tew
Name of Director or Senior Officer


Signature

Corporate Secretary
Official Capacity

Issuer Details Name of Issuer Sativa Wellness Group Inc.	For Month End April 2021	Date of Report 04/31/21
Issuer Address Suite 409 – 221 503-905 Pender St. W. Esplanade,		
City/Province/Postal Code Vancouver/BC/V7M 3J3	Issuer Fax No. ()	Issuer Telephone No. ()
Contact Name Anne Tew	Contact Position Corporate Secretary	Contact Telephone No. +44 (0) 13 7348 2482
Contact Email Address anne@sativawellnessgroup.com	Web Site Address www.sativawellnessgroup.com	

FORM 7 – MONTHLY PROGRESS REPORT